{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:54:31Z","timestamp":1784120071183,"version":"3.55.0"},"reference-count":80,"publisher":"Informa UK Limited","funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1\u2013014"],"award-info":[{"award-number":["2021-I2M-1\u2013014"]}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L248025"],"award-info":[{"award-number":["L248025"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"DOI":"10.1080\/14740338.2026.2674136","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:56:27Z","timestamp":1778594187000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury"],"prefix":"10.1080","author":[{"given":"Liyi","family":"Chen","sequence":"first","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5767-5127","authenticated-orcid":false,"given":"Chun-Yu","family":"Li","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.09.012"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.04.030"},{"issue":"4","key":"e_1_3_5_5_1","first-page":"Cd006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"2012","author":"Moja L","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;2012(4):Cd006243.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33726"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1142"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15643"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3621"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac107"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104355"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1890710"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz263.007"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01361"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1041"},{"key":"e_1_3_5_18_1","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD); 2012. Available from cited 2025 Feb 7]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548559"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0012"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.990087"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae141"},{"issue":"10","key":"e_1_3_5_24_1","first-page":"2307","article-title":"Chinese expert consensus on the clinical management of liver disease-associated thrombocytopenia syndrome","volume":"39","author":"Yu H","year":"2023","unstructured":"Yu H, Yan T, Sun Y. Chinese expert consensus on the clinical management of liver disease-associated thrombocytopenia syndrome. J Clin Hepatol. 2023;39(10):2307\u20132320.","journal-title":"J Clin Hepatol"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076065"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914609"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30536-2"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02420-5"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30111-0"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1590"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00380-2"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00215-2"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30465-4"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241304680"},{"issue":"12","key":"e_1_3_5_35_1","first-page":"993","article-title":"The expert consensus on the safety management of targeted therapy drugs for breast cancer in China","volume":"29","author":"Chinese Society of Clinical Oncology Breast Cancer Committee","year":"2019","unstructured":"Chinese Society of Clinical Oncology Breast Cancer Committee. The expert consensus on the safety management of targeted therapy drugs for breast cancer in China. China Oncol. 2019;29(12):993\u20131006.","journal-title":"China Oncol"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS21-P5-18-03"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.33448\/rsd-v10i8.17005"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-019-00392-4"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/hpb.12047"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1434492"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0012.7207"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.081"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000784664.38318.bb"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.8543"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1159\/000521933"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00124"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i7.706"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.024"},{"issue":"1","key":"e_1_3_5_49_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.29289\/259453942024V34S1104","article-title":"Case report: sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine in breast cancer","volume":"34","author":"Barbosa ACS","year":"2024","unstructured":"Barbosa ACS, Resende CAA, Rocha HC, et al. Case report: sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine in breast cancer. Mastology. 2024;34(Suppl 1):104.","journal-title":"Mastology"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1816149"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0580"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu160"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32873"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100188"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1159\/000346844"},{"issue":"2","key":"e_1_3_5_57_1","first-page":"1","article-title":"Drug-induced liver injury (DILI) in luminal B\/Her2-enriched breast cancer patient during adjuvant trastuzumab: case report and literature review","volume":"3","author":"Bazzoli M","year":"2023","unstructured":"Bazzoli M, Zucchini N, Capici S, et al. Drug-induced liver injury (DILI) in luminal B\/Her2-enriched breast cancer patient during adjuvant trastuzumab: case report and literature review. Int Case Rep J. 2023;3(2):1\u20139.","journal-title":"Int Case Rep J"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61847-3"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.08.020"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.86746"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1560"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S339092"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(24)04367-1"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbab005"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1369-3"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2007.01.012"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26461"},{"issue":"12","key":"e_1_3_5_68_1","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su Z","year":"2021","unstructured":"Su Z, Xiao D, Xie F, et al. Antibody-drug conjugates: recent advances in linker chemistry. Acta Pharm Sin B. 2021;11(12):3889\u20133907.","journal-title":"Acta Pharm Sin B"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc500357n"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11113080"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2093"},{"key":"e_1_3_5_72_1","unstructured":"BioRender. Available from cited 2025 May 5]. Available from: https:\/\/www.biorender.com\/"},{"issue":"7","key":"e_1_3_5_73_1","first-page":"23","article-title":"Spider telangiectases and Palmar Erythema as harbingers of structural liver changes in three breast cancer patients on ado-trastuzumab emtansine","volume":"12","author":"Milam P","year":"2019","unstructured":"Milam P, Berger M, Ramaswamy B, et al. Spider telangiectases and Palmar Erythema as harbingers of structural liver changes in three breast cancer patients on ado-trastuzumab emtansine. J Clin Aesthet Dermatol. 2019;12(7):23\u201326.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.007"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70038"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32327"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz189"},{"issue":"2","key":"e_1_3_5_78_1","first-page":"154","article-title":"Current status and future perspectives of antibody-drug conjugates in breast cancer therapy","volume":"35","author":"Lin J","year":"2025","unstructured":"Lin J, Wang W, Xu B. Current status and future perspectives of antibody-drug conjugates in breast cancer therapy. China Oncol. 2025;35(2):154\u2013166.","journal-title":"China Oncol"},{"issue":"9","key":"e_1_3_5_79_1","first-page":"913","article-title":"Chinese medical doctor association; International medical exchange society, Chinese anti-cancer association. Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer","volume":"44","author":"Breast Cancer Group BoO","year":"2022","unstructured":"Breast Cancer Group BoO. Chinese medical doctor association; International medical exchange society, Chinese anti-cancer association. Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer. Chin J Oncol. 2022;44(9):913\u2013927.","journal-title":"Chin J Oncol"},{"key":"e_1_3_5_80_1","unstructured":"European Medicines Agency. Kadcyla (trastuzumab emtansine): summary of product characteristics. 2018. Available from cited 2025 May 5]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/rmp\/kadcyla-epar-risk-management-plan_en.pdf"},{"issue":"4","key":"e_1_3_5_81_1","first-page":"304","article-title":"Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)","volume":"46","author":"Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group","year":"2024","unstructured":"Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group. Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition). Chin J Oncol. 2024;46(4):304\u2013318.","journal-title":"Chin J Oncol"},{"key":"e_1_3_5_82_1","unstructured":"Roche Pharma (Schweiz) AG. Kadcyla (trastuzumab emtansine). 2024 [cited 2025 May 5. Available from: https:\/\/assets.roche.com\/f\/249469\/x\/00e95aac02\/zhusheyongenmeiqutuozhudankang_20240604.pdf"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2026.2674136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T04:15:20Z","timestamp":1779077720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2026.2674136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":80,"alternative-id":["10.1080\/14740338.2026.2674136"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2026.2674136","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}